Amerigen’s growth business development strategy is focused on three key principles: internal product development; collaborative development; and in-licensing/acquisitions of products and technologies.

愛美津制藥全球業務發展戰略包含三個方面：內部產品開發、合作開發、以及產品與技術和許可和并購。

In the US market, Amerigen is committed in developing generic and complex products with a robust pipeline of more than 30 ANDAs, half of them are high value First-to-File (FTF) opportunities. In the China market, excepting for commercializing Amerigen’s existing portfolio of approved products, Amerigen is bringing selected complex US ANDAs to China, following the recent regulations by CFDA.

在美國市場，愛美津致力于高難度仿制藥的開發，目前已經擁有了30多個產品的產品線，其中近一半是高附加值的首報產品（First-to-file Product）。在中國市場，除了銷售與合作目前已經獲批的產品之外，愛美津順應目前中國政府的改革，目前正選擇性的將美國的高難度仿制藥產品引入到中國市場。

As we expand our China pharmaceuticals business, Amerigen is committed to seeking local partnerships that fit our capabilities, enhance our corporate goals and strengthen our competitive position. We regard partnership and collaboration as an integral part of our China business development strategy. This important initiative is supported by a local BD team.

目前我們正在積極開拓中國市場的業務，愛美津希望尋求本土的合作機會，能夠符合公司的戰略目標、適合公司的核心競爭力并能夠提升公司的競爭地位。這類合作是中國業務拓展戰略非常重要的一部分，目前由本土的業務拓展團隊負責。

Besides US and China market, Amerigen will also evaluate opportunities in other territories if they may provide strategic returns for the company.

除了美國和中國市場，愛美津也會評估其它國家/地域的機會，如果這些機會能夠給公司帶來戰略上的回報。

 

If your firm is interested in working with Suzhou Amerigen, contact us.